Sinovac Biotech (NASDAQ: SVA) is one of 49 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it compare to its peers? We will compare Sinovac Biotech to related businesses based on the strength of its analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Institutional and Insider Ownership
30.7% of Sinovac Biotech shares are owned by institutional investors. Comparatively, 45.8% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 16.5% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Risk & Volatility
Sinovac Biotech has a beta of 0.1, meaning that its stock price is 90% less volatile than the S&P 500. Comparatively, Sinovac Biotech’s peers have a beta of 1.21, meaning that their average stock price is 21% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Sinovac Biotech and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sinovac Biotech Competitors||128||792||1730||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 14.23%. Given Sinovac Biotech’s peers higher possible upside, analysts plainly believe Sinovac Biotech has less favorable growth aspects than its peers.
This table compares Sinovac Biotech and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sinovac Biotech Competitors||-13,514.61%||-103.41%||-26.54%|
Earnings and Valuation
This table compares Sinovac Biotech and its peers revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Sinovac Biotech||$67.41 million||-$1.07 million||-65.64|
|Sinovac Biotech Competitors||$604.20 million||$110.82 million||56.09|
Sinovac Biotech’s peers have higher revenue and earnings than Sinovac Biotech. Sinovac Biotech is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Sinovac Biotech peers beat Sinovac Biotech on 6 of the 9 factors compared.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
Receive News & Ratings for Sinovac Biotech Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinovac Biotech Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.